Suwasin Udomkarnjananun1, Kullaya Takkavatakarn1, Kearkiat Praditpornsilpa1, Claudia Nader2,3, Somchai Eiam-Ong1, Bertrand L Jaber2,3, Paweena Susantitaphong4,5. 1. Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, 10330, Thailand. 2. Department of Medicine, St. Elizabeth's Medical Center, Boston, MA, USA. 3. Department of Medicine, Tufts University School of Medicine, Boston, MA, USA. 4. Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, 10330, Thailand. pesancerinus@hotmail.com. 5. Research Unit for Metabolic Bone Disease in CKD Patients, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. pesancerinus@hotmail.com.
Abstract
BACKGROUND: We performed a systematic review and meta-analysis to examine factors associated with HBV immune response in dialysis patients, and the association between the immune response to the HBV vaccine and mortality. METHODS: Electronic databases were searched for studies of dialysis patients that compared the characteristics of HBV vaccine responders and non-responders. Mortality was also analyzed according to the vaccine immune response (defined by hepatitis B surface antibody titer > 10 mIU/mL). Random-effects model meta-analyses were performed to compute a weighted mean difference (WMD), a pooled odds ratio (OR), and a pooled risk ratio (RR) between groups. RESULTS: We identified 61 studies with a total of 6628 dialysis patients who completed the course of HBV vaccination, 4582 responders (69%) and 2046 non-responders (31%). By meta-analysis, relative to non-responders, HBV vaccine responders had a higher dialysis adequacy as measured by Kt/V (WMD 0.08, P < 0.001), a higher serum albumin (WMD 0.12 gm/dL, P < 0.001), a higher normalized protein catabolic rate (WMD 0.12 gm/kg/day, P = 0.001), a higher hemoglobin (WMD 0.15 gm/L, P = 0.03), and a higher parathyroid hormone level (WMD 44 pg/mL, P = 0.004). HBV vaccine responders were younger (WMD - 4.68 years, P < 0.001), had been on dialysis for longer (WMD 2.60 months, P < 0.001), were less likely to have diabetes mellitus (pooled OR 0.65, P < 0.001), and were less likely to carry the human leukocyte antigen (HLA) DR3 (pooled OR 0.38, P = 0.01). Compared to non-responders, HBV vaccine responders had lower risk for all-cause mortality (pooled RR 0.64, P < 0.001), and lower risk for cardiovascular-related mortality (pooled RR 0.74, P = 0.02). CONCLUSION: In dialysis patients, the lack of immune response to the HBV vaccine is associated with older age, diabetes mellitus, HLA-DR3 status, shorter time on dialysis, lower nutritional status, lower hemoglobin, lower PTH level, and lower dialysis adequacy. Tackling some of these modifiable factors might improve the HBV vaccine immune response.
BACKGROUND: We performed a systematic review and meta-analysis to examine factors associated with HBV immune response in dialysis patients, and the association between the immune response to the HBV vaccine and mortality. METHODS: Electronic databases were searched for studies of dialysis patients that compared the characteristics of HBV vaccine responders and non-responders. Mortality was also analyzed according to the vaccine immune response (defined by hepatitis B surface antibody titer > 10 mIU/mL). Random-effects model meta-analyses were performed to compute a weighted mean difference (WMD), a pooled odds ratio (OR), and a pooled risk ratio (RR) between groups. RESULTS: We identified 61 studies with a total of 6628 dialysis patients who completed the course of HBV vaccination, 4582 responders (69%) and 2046 non-responders (31%). By meta-analysis, relative to non-responders, HBV vaccine responders had a higher dialysis adequacy as measured by Kt/V (WMD 0.08, P < 0.001), a higher serum albumin (WMD 0.12 gm/dL, P < 0.001), a higher normalized protein catabolic rate (WMD 0.12 gm/kg/day, P = 0.001), a higher hemoglobin (WMD 0.15 gm/L, P = 0.03), and a higher parathyroid hormone level (WMD 44 pg/mL, P = 0.004). HBV vaccine responders were younger (WMD - 4.68 years, P < 0.001), had been on dialysis for longer (WMD 2.60 months, P < 0.001), were less likely to have diabetes mellitus (pooled OR 0.65, P < 0.001), and were less likely to carry the human leukocyte antigen (HLA) DR3 (pooled OR 0.38, P = 0.01). Compared to non-responders, HBV vaccine responders had lower risk for all-cause mortality (pooled RR 0.64, P < 0.001), and lower risk for cardiovascular-related mortality (pooled RR 0.74, P = 0.02). CONCLUSION: In dialysis patients, the lack of immune response to the HBV vaccine is associated with older age, diabetes mellitus, HLA-DR3 status, shorter time on dialysis, lower nutritional status, lower hemoglobin, lower PTH level, and lower dialysis adequacy. Tackling some of these modifiable factors might improve the HBV vaccine immune response.
Authors: Michael Paal; Florian M Arend; Tobias Lau; Sandra Hasmann; Daniela Soreth-Rieke; Johanna Sorodoc-Otto; Wilke Beuthien; Julia Krappe; Marcell Toepfer; Gero von Gersdorff; Norbert Thaller; Simon Rau; Bernd Northoff; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck Journal: Clin Kidney J Date: 2021-07-06
Authors: Louise Füessl; Tobias Lau; Isaac Lean; Sandra Hasmann; Bernhard Riedl; Florian M Arend; Johanna Sorodoc-Otto; Daniela Soreth-Rieke; Marcell Toepfer; Simon Rau; Haxhrije Salihi-Halimi; Michael Paal; Wilke Beuthien; Norbert Thaller; Yana Suttmann; Gero von Gersdorff; Ron Regenauer; Anke von Bergwelt-Baildon; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck Journal: Vaccines (Basel) Date: 2022-04-13
Authors: Hal Drakesmith; Sant-Rayn Pasricha; Ioav Cabantchik; Chaim Hershko; Guenter Weiss; Domenico Girelli; Nicole Stoffel; Martina U Muckenthaler; Elizabeta Nemeth; Clara Camaschella; Paul Klenerman; Michael B Zimmermann Journal: Lancet Haematol Date: 2021-09 Impact factor: 18.959
Authors: André Weigert; Marie-Louise Bergman; Lígia A Gonçalves; Iolanda Godinho; Nádia Duarte; Rita Abrantes; Patrícia Borges; Ana Brennand; Vanessa Malheiro; Paula Matoso; Onome Akpogheneta; Lindsay Kosack; Pedro Cruz; Estela Nogueira; Magda Pereira; Ana Ferreira; Marco Marques; Telmo Nunes; João Faro-Viana; Jocelyne Demengeot; Carlos Penha-Gonçalves Journal: Front Med (Lausanne) Date: 2021-12-24
Authors: Eduardo Lacson; Christos P Argyropoulos; Harold J Manley; Gideon Aweh; Andrew I Chin; Loay H Salman; Caroline M Hsu; Doug S Johnson; Daniel E Weiner Journal: J Am Soc Nephrol Date: 2021-08-04 Impact factor: 10.121
Authors: Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath Journal: Kidney Int Rep Date: 2021-07-06